Tags

Type your tag names separated by a space and hit enter

Randomised double-blind placebo-controlled trial of feverfew in migraine prevention.
Lancet 1988; 2(8604):189-92Lct

Abstract

The use of feverfew (Tanacetum parthenium) for migraine prophylaxis was assessed in a randomised, double-blind, placebo-controlled crossover study. After a one-month single-blind placebo run-in, 72 volunteers were randomly allocated to receive either one capsule of dried feverfew leaves a day or matching placebo for four months and then transferred to the other treatment limb for a further four months. Frequency and severity of attacks were determined from diary cards which were issued every two months; efficacy of each treatment was also assessed by visual analogue scores. 60 patients completed the study and full information was available in 59. Treatment with feverfew was associated with a reduction in the mean number and severity of attacks in each two-month period, and in the degree of vomiting; duration of individual attacks was unaltered. Visual analogue scores also indicated a significant improvement with feverfew. There were no serious side-effects.

Authors+Show Affiliations

Department of Medicine, University Hospital, Nottingham.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

2899663

Citation

Murphy, J J., et al. "Randomised Double-blind Placebo-controlled Trial of Feverfew in Migraine Prevention." Lancet (London, England), vol. 2, no. 8604, 1988, pp. 189-92.
Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2(8604):189-92.
Murphy, J. J., Heptinstall, S., & Mitchell, J. R. (1988). Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet (London, England), 2(8604), pp. 189-92.
Murphy JJ, Heptinstall S, Mitchell JR. Randomised Double-blind Placebo-controlled Trial of Feverfew in Migraine Prevention. Lancet. 1988 Jul 23;2(8604):189-92. PubMed PMID: 2899663.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. AU - Murphy,J J, AU - Heptinstall,S, AU - Mitchell,J R, PY - 1988/7/23/pubmed PY - 1988/7/23/medline PY - 1988/7/23/entrez SP - 189 EP - 92 JF - Lancet (London, England) JO - Lancet VL - 2 IS - 8604 N2 - The use of feverfew (Tanacetum parthenium) for migraine prophylaxis was assessed in a randomised, double-blind, placebo-controlled crossover study. After a one-month single-blind placebo run-in, 72 volunteers were randomly allocated to receive either one capsule of dried feverfew leaves a day or matching placebo for four months and then transferred to the other treatment limb for a further four months. Frequency and severity of attacks were determined from diary cards which were issued every two months; efficacy of each treatment was also assessed by visual analogue scores. 60 patients completed the study and full information was available in 59. Treatment with feverfew was associated with a reduction in the mean number and severity of attacks in each two-month period, and in the degree of vomiting; duration of individual attacks was unaltered. Visual analogue scores also indicated a significant improvement with feverfew. There were no serious side-effects. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/2899663/Randomised_double_blind_placebo_controlled_trial_of_feverfew_in_migraine_prevention_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(88)92289-1 DB - PRIME DP - Unbound Medicine ER -